key: cord-1050667-eqalzjbm
authors: Townsend, Liam; Fogarty, Helen; Dyer, Adam; Martin‐Loeches, Ignacio; Bannan, Ciaran; Nadarajan, Parthiban; Bergin, Colm; O’Farrelly, Cliona; Conlon, Niall; Bourke, Nollaig M.; Ward, Soracha E.; Byrne, Mary; Ryan, Kevin; O’Connell, Niamh; O’Sullivan, Jamie M.; Ni Cheallaigh, Cliona; O’Donnell, James S.
title: Prolonged elevation of D‐dimer levels in convalescent COVID‐19 patients is independent of the acute phase response
date: 2021-03-08
journal: J Thromb Haemost
DOI: 10.1111/jth.15267
sha: c55362d32594abf50c0294e1167ebb7aac8df1e7
doc_id: 1050667
cord_uid: eqalzjbm

BACKGROUND: Persistent fatigue, breathlessness, and reduced exercise tolerance have been reported following acute COVID‐19 infection. Although immuno‐thrombosis has been implicated in acute COVID‐19 pathogenesis, the biological mechanisms underpinning long COVID remain unknown. We hypothesized that pulmonary microvascular immuno‐thrombosis may be important in this context. METHODS: One hundred fifty COVID‐19 patients were reviewed at St James's Hospital Dublin between May and September 2020 at a median of 80.5 (range 44–155) days after initial diagnosis. These included patients hospitalized during initial illness (n = 69) and others managed entirely as out‐patients (n = 81). Clinical examination, chest x‐ray, and 6‐min walk tests were performed. In addition, a range of coagulation and inflammatory markers were assessed. RESULTS: Increased D‐dimer levels (>500 ng/ml) were observed in 25.3% patients up to 4 months post‐SARS‐CoV‐2 infection. On univariate analysis, elevated convalescent D‐dimers were more common in COVID‐19 patients who had required hospital admission and in patients aged more than 50 years (p < .001). Interestingly, we observed that 29% (n = 11) of patients with elevated convalescent D‐dimers had been managed exclusively as out‐patients during their illness. In contrast, other coagulation (prothrombin time, activated partial thromboplastin time, fibrinogen, platelet count) and inflammation (C‐reactive protein, interleukin‐6, and sCD25) markers had returned to normal in >90% of convalescent patients. CONCLUSIONS: Elucidating the biological mechanisms responsible for sustained D‐dimer increases may be of relevance in long COVID pathogenesis and has implications for clinical management of these patients.

The coronavirus SARS-CoV-2 is responsible for the current global pandemic that has resulted in significant morbidity and mortality. 1 Features of the acute illness are well described, ranging from mild disturbance in smell and coryzal symptoms to acute respiratory failure and the need for mechanical ventilation. 2, 3 Changes in coagulation parameters are common in patients presenting with acute COVID-19. In particular, elevated plasma levels of fibrin degradation D-dimers represent a common finding in hospitalized patients.

Furthermore, progressive increases in D-dimers in COVID-19 are associated with significantly worse clinical outcomes. 4 In keeping with coagulation activation in severe COVID-19, high rates of thrombotic complications, particularly pulmonary emboli, have also been described. 5 These data led to initial suggestions that D-dimer levels may have a role to play in decisions regarding clinical management for patients with SARS-CoV-2 infection. 6 Importantly, the biological mechanisms underpinning the elevated plasma D-dimer levels associated with COVID-19 remain poorly understood. Initial studies from Wuhan, China suggested that the increase in D-dimers was associated with disseminated intravascular coagulopathy (DIC). 7 In contrast, however, more recent studies from Europe and North America suggest that overt DIC is actually rare in COVID-19 patients receiving prophylactic dose low molecular weight heparin (LMWH). Nevertheless, high D-dimer levels remain a consistent finding in this latter cohort despite their anticoagulant therapy. In addition, elevated D-dimers have been shown to be an independent biomarker for poor prognosis even in COVID-19 patients being treated with LMWH. 8 In this context, ongoing clinical trials are comparing the efficacy and safety of different doses of LMWH in COVID-19. Moreover, extended duration anticoagulant therapy has been proposed for COVID-19 patients following discharge, particularly after prolonged intensive care unit (ICU) admission.

Evidence is emerging of persistent symptoms following acute SARS-CoV-2 illness in a high proportion of patients. This "long COVID" phenomenon has been defined as "not recovering for several weeks or months following the start of symptoms that were suggestive of COVID." 9 Although fatigue, breathlessness, and reduced exercise tolerance have been reported as common features, 10 the pathological mechanisms underlying these persistent symptoms remain unknown. Given the role of coagulation activation, fibrinolysis, and pulmonary micro-vascular immunothrombosis in acute COVID-19 pathogenesis, we hypothesized that similar mechanisms may also be important in long COVID. To address this hypothesis, we investigated clinical parameters together with coagulation and inflammation biomarkers in COVID-19 patients during convalescence. Results: Increased D-dimer levels (>500 ng/ml) were observed in 25.3% patients up to 4 months post-SARS-CoV-2 infection. On univariate analysis, elevated convalescent D-dimers were more common in COVID-19 patients who had required hospital admission and in patients aged more than 50 years (p < .001). Interestingly, we observed that 29% (n = 11) of patients with elevated convalescent D-dimers had been managed exclusively as out-patients during their illness. In contrast, other coagulation (prothrombin time, activated partial thromboplastin time, fibrinogen, platelet count) and inflammation (C-reactive protein, interleukin-6, and sCD25) markers had returned to normal in >90% of convalescent patients.

Elucidating the biological mechanisms responsible for sustained D-dimer increases may be of relevance in long COVID pathogenesis and has implications for clinical management of these patients. • Further adequately powered studies will be required to elucidate the mechanisms underlying elevated D-dimer levels during COVID-19 convalescence. Abnormal chest X-ray n (%) 14 (9) 7 (6) 7 (18) Notes:: The demographic data and laboratory results are shown for the entire cohort (n = 150 patients). In addition, the cohort have been subdivided into patients with either normal or elevated D-dimer levels at time of out-patient assessment.

Abbreviations: 6 MWT, 6 min walk test; APTT, activated partial thromboplastin time; BMI, body mass index; CRP, C-reactive protein; IL-6, interleukin-6; IQR, interquartile range; PT, prothrombin time. Univariate analysis was performed on important demographic and acute illness variables to examine differences between those with elevated convalescent D-dimers and those with normal D-dimers, using t-test, Wilcoxon rank-sum, and Chi-squared test as appropriate. Multivariate analysis was then performed (see Appendix S1 in supporting information for details) to explore potential predictors of elevated D-dimer. Figure 1A) . Median Ddimer levels in this subgroup was 744 ng/ml (range 504-6726 ng/ ml). Furthermore, 12/150 (8%) of the COVID-19 patients studied during recovery phase had markedly increased D-dimer levels more than twice the upper limit of normal (ULN). On univariate analysis, elevated convalescent D-dimers were significantly more common among COVID-19 patients who had required hospital admission compared to those with mild disease (X 2 12.86; p < .001; Table 1 , Figure 1A ). Nevertheless, significant inter-individual variability in Ddimer levels during convalescence was observed even among hospitalised COVID-19 patients ( Figure 1A) . For example, D-dimer levels had normalized by time of review in 10/16 (62.5%) patients who had required ICU support. Interestingly, we observed that 29% (n = 11) of patients with abnormally elevated D-dimer at time of follow-up had been managed exclusively as out-patients during their illness ( Figure 1A) . On univariate analysis, elevated convalescent D-dimers were significantly more frequent in patients aged >50 years (t −3.98 p < .001) and in those with comorbidities (comorbidity count -z 2.03 p < .001; Table 1, Figure 1B) . Collectively, these novel data demonstrate that sustained elevations in D-dimers are a common finding in patients following SARS-CoV-2 infection and occur more frequently in those with severe acute disease and in older patients.

To investigate the biological mechanisms responsible for the sustained increase in D-dimers, we investigated other coagulation and inflammatory markers in convalescent COVID-19 patients. In contrast to the D-dimer results, PT and APTT had returned to normal range in a much larger proportion of patients ( Figure 1C , Table 1 ).

Moreover, convalescent patients had no evidence of hypofibrinogenemia ( Figure 1D ) or thrombocytopenia (Table 1) Figure 1E ), increased IL-6 levels in 10/150 (6.7%; Figure 1F ), and increased sCD25 in only 6/150 (4%; Figure 1G ) of convalescent COVID-19 patients. Some patients with ongoing elevated inflammatory markers also had elevated D-dimer levels ( Figure 1H ).

Importantly, however, all three inflammatory markers (CRP, IL-6, and sCD25) were within the normal range in the majority of convalescent COVID-19 patients with elevated D-dimers (26/38; 68.5%).

Multivariate analysis was used to explore potential predictors of elevated convalescent D-dimers. For COVID-19 patients who had required hospitalization, the relationship between elevated D-dimer levels and previous coagulation-inflammation assays performed during acute SARS-CoV-2 illness was investigated. Elevated Ddimers at follow-up had no relationship with peak D-dimers, fibrinogen, platelets, or CRP (Table S1 in supporting information). Similarly, no significant relationships were observed between elevated convalescent D-dimers and other markers of coagulation or inflammation at convalescence, or time to follow-up Table S1 ). The relationship between acute illness severity and age with elevated convalescent Ddimers was not seen on multivariate analysis. Finally, we examined the relationship between elevated convalescent D-dimers and clinical features in convalescent COVID-19 patients. Ongoing symptoms consistent with long COVID were common in our cohort. Seventyseven patients (51%) met the case definition for fatigue, 43 of whom (43/77, 56%) had experienced mild COVID-19 and were managed entirely as out-patients. On univariate analysis, abnormal chest

x-rays during convalescence were more common in patients with elevated D-dimers compared to patients in whom D-dimer levels were within normal range (χ 2 6.01, p = .01). However, on multivariate analysis, there was no relationship between any of the clinical parameters assessed and elevated convalescent D-dimers (Table S2 in supporting information).

Notwithstanding the limited size of our cohort, the lack of a com- In conclusion, our findings clearly demonstrate that elevation in D-dimers is a common finding in COVID-19 patients during convalescence. Importantly, this increase in D-dimer was seen at a median of greater than 2 months following resolution of acute COVID-19 infection and was observed in a cohort comprising predominantly young patients (median age 47 years) who mostly (64%) recovered without hospitalization. Interestingly, the increase in convalescent Ddimers remained despite normalization of inflammatory markers and other coagulation parameters in most patients. Further adequately powered studies will be required to elucidate the mechanisms underpinning elevated D-dimer levels during recovery phase. However, previous studies have highlighted disturbances in the balance between pulmonary coagulation and fibrinolytic pathways in models of acute respiratory distress syndrome, pneumonia, and ventilatorassociated lung injury. [16] [17] [18] Furthermore, it seems likely that extravascular pulmonary fibrinolysis may be important in the etiology of elevated D-dimers during COVID-19 recovery. Given emerging data regarding post-infection long COVID syndrome, as well as ongoing discussions regarding optimal duration of thromboprophylaxis in COVID-19 patients following discharge, defining these mechanisms may be of direct clinical relevance.

Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study

Prevalence of smell and taste dysfunction in a cohort of CoVID19 outpatients managed through remote consultation from a large urban teaching hospital in

Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study

COVID19 coagulopathy in Caucasian patients

Pulmonary embolism in patients with coronavirus disease-2019 (COVID-19) pneumonia: a narrative review

Intensity of anticoagulation and survival in patients hospitalized with COVID-19 pneumonia

Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia

D-dimer as an indicator of prognosis in SARS-CoV-2 infection: a systematic review

Management of post-acute covid-19 in primary care

Persistent fatigue following SARS-CoV-2 infection is common and independent of severity of initial infection

World Medical Association Declaration of Helsinki. Ethical principles for medical research involving human subjects

COVID-19 coagulopathy in Caucasian patients

Development of a fatigue scale

The Chalder fatigue scale (CFQ 11)

More on COVID-19 coagulopathy in Caucasian patients

Bronchoalveolar hemostasis in lung injury and acute respiratory distress syndrome

Endothelial cells orchestrate COVID-19 coagulopathy

Immune mechanisms of pulmonary intravascular coagulopathy in COVID-19 pneumonia

This work was performed within the Irish Clinical Academic Training